DecisionDx-UM & PRAME
Uveal Melanoma
Commercial/Ongoing ValidationActive
Key Facts
About Castle Biosciences
Castle Biosciences is a mission-driven company focused on transforming disease management by applying precision genomics to high-stakes clinical decisions. Since its 2008 founding, it has built a commercially successful portfolio of proprietary tests, supported by over 150 peer-reviewed publications and more than 300,000 test reports delivered. Its strategy centers on addressing critical unmet needs in dermatologic, ocular, and gastrointestinal oncology through its multi-analyte GEP platform, driving growth via clinical validation, payer coverage, and market penetration.
View full company profileTherapeutic Areas
Other Uveal Melanoma Drugs
| Drug | Company | Phase |
|---|---|---|
| EIR-1003 | EIR Biopharma | Preclinical |
| Tebentafusp (Kimmtrak) | Ono Pharmaceutical | Approved |
| Avutometinib + Defactinib | Verastem Oncology | Phase 1/2 |